Post-transplant lymphoproliferative disorder · 5 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
R, then CHOP Variant #01 | — | R 48 052 | 56d | — | — | — | — | — |
R-CP Variant #01 | — | R 35 814 | 21d | — | — | — | — | — |
ACVBP, dose-adjusted Variant #01 Partial | — | R 737 | 14d | — | — | — | — | — |
Rituximab monotherapy N/A - secondary systemic drug | — | R 52 | 180d | ~20.3 mo | — | ~4 | ~R 208 PFS proxy · indirect | 20 |
Reduction of immunosuppression Partial | — | — | — | — | — | — | — | — |
5 of 5 regimens shown